Aspergillosis Treatment Market Size was valued at USD 3.2 Billion in 2023. The aspergillosis treatment market industry is projected to grow from USD 3.3 Billion in 2024 to USD 4.7 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.10% during the forecast period (2024 - 2032). Major market drivers predicted to make contributions to aspergillosis remedy market enlargement favorably encompass the growing prevalence of the goal situation and the growing emphasis on the improvement of progressive medications.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
The market for aspergillosis treatment is predicted to increase in the future due to the rising prevalence of fungal infections. Fungi are the source of fungal infections, which are also known as mycosis. Both human beings and animals may emerge as infected with it as well. Aspergillosis is a fungal illness that may affect the kidneys, mind, lungs, breathing gadgets, and different organs. Voriconazole is one aspergillosis medication that attempts to manage fungal contamination, lessen signs, forestall outcomes, and enhance trendy fitness. For instance, in July 2023, the United States public fitness agency Centers for Disease Control and Prevention (CDC) suggested that the prices of fungal hospitalizations rose from 22.3 in 2019 to twenty-five. Zero in 2020 and 26.8 in 2021, representing a mean annual increase of eight. Five per 10,000 hospitalizations. Thus, the market for aspergillosis treatment is expanding due to the rising occurrence of fungal sicknesses.
Furthermore, the market for aspergillosis treatment is anticipated to develop in the future due to the increase in healthcare costs. All expenses associated with delivering family planning services, dietary plans, emergency assistance, and health-focused services are referred to as health expenditures. An increase in healthcare spending would lead to the creation of aspergillosis treatment-related medications and technological advancements. For instance, in March 2023, the US-based professional body American Medical Association reported that US health care spending climbed 2.7% to $12,914 per person in 2021, or $4.3 trillion. As a result, the market for aspergillosis treatment is expanding due to rising healthcare costs.
In addition, to hold their market share, predominant gamers inside the aspergillosis treatment enterprise are focusing on launching cutting-edge aspergillosis medicinal drugs and remedies. The introduction of the latest capsules expands the variety of available remedies for aspergillosis. One such medicine is posaconazole oral suspension, which offers patients more specialized and efficient care. For instance, the UK-based pharmaceutical business enterprise Hikma Pharmaceuticals PLC added Posaconazole oral suspension for the treatment of aspergillosis inside the US in April 2023. Thus, driving the aspergillosis treatment market revenue.
The Aspergillosis Treatment Market segmentation, based on type, includes Allergic, Chronic, and Invasive Aspergillosis. In 2023, the allergic segment dominated the market because, in comparison to other forms, it has a larger prevalence and a milder illness presentation. Asthma and cystic fibrosis patients are susceptible to conditions like ABPA, which cause inflammation and respiratory symptoms in the lungs due to an allergic reaction to Aspergillus antigens.
The Aspergillosis Treatment Market segmentation, based on drug class, includes Corticosteroids, Anti-fungal, and Others. The anti-fungal category generated the most income in 2023. The commercial domination of anti-fungal medications can be ascribed to their efficaciousness against infections and their extensive application as the principal therapeutic choice. The segment's relevance is predicted to be sustained by healthcare providers' focus on creating more effective and focused anti-fungal medicines, which will propel market expansion overall.
Figure 1: Aspergillosis Treatment Market, by Drug Class, 2023 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
The Aspergillosis Treatment Market segmentation, based on the route of administration, includes Oral Drugs, Ointments, Powders, and Others. The oral drugs category generated the most income in 2023. Its expansion has been facilitated by its ease of use and patient-friendly administration, which have made it popular with both patients and healthcare professionals. Oral medications ease self-administration and compliance at home when given for a prolonged duration, reducing the burden on patients and healthcare facilities. Better formulations of oral anti-fungal medication have also been produced as the field has grown, which has improved the pill's ability to treat sickness.
The Aspergillosis Treatment Market segmentation, based on distribution channel, includes Hospital Pharmacy, Retail Pharmacy, and Others. The hospital pharmacy category generated the most income in 2023. The vital role hospital-based distribution channels play in the effective and convenient delivery of healthcare is the driving force behind this expansion. Customers' preference for hospital pharmacies shapes the market environment because they trust these establishments to manage the complex medical needs associated with treatment.
By region, the study provides the market insights into North America, Europe, Asia-Pacific and the Rest of the World. The North American aspergillosis treatment market area will dominate this market. This region is expected to increase throughout the projected period due to factors like FDA approvals, new product launches, the expansion of the healthcare infrastructure, and the rise in clinical studies conducted by various institutes and research industries.
Further, the major countries studied in the market report are the US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, and South Korea.
Figure 2: Aspergillosis Treatment Market Share By Region 2023 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe's aspergillosis treatment market accounts for the second-largest market share ascribed to elements such as the existence of major market participants, growing per capita healthcare spending, and rising disease prevalence in the area. Further, the German aspergillosis treatment market held the largest market share, and the UK aspergillosis treatment market was the fastest growing market in the European region.
The Asia-Pacific Aspergillosis Treatment Market is expected to grow at the fastest CAGR from 2024 to 2032, propelled by elements including FDA approvals, the launch of new goods, the building of the healthcare system, and an increase in the number of clinical trials carried out by different organizations and research sectors. Moreover, China’s aspergillosis treatment market held the largest market share, and the Indian aspergillosis treatment market was the fastest growing market in the Asia-Pacific region.
Leading market players are investing heavily in research and development in order to expand their product lines, which will help the aspergillosis treatment market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their global footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, the aspergillosis treatment industry must offer cost-effective items.
Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the global aspergillosis treatment industry to benefit clients and increase the market sector. In recent years, the aspergillosis treatment industry has offered some of the most significant advantages to medicine. Major players in the aspergillosis treatment market are attempting to increase market demand by investing in research and development operations, including Pfizer, Inc., Astellas Pharma Inc., F2G, Merck & Co., PULMATRiX, Inc., Novartis AG, Mayne Pharma Group Limited, and Bayer AG.
A specialist pharmaceutical company called Mayne Pharma Group Ltd. (Mayne Pharma) produces and distributes both branded and generic medications. Additionally, it provides pharmaceutical development, analytical testing, and commercial manufacturing services under contract development and CDMO agreements. The US FDA approved Mayne Pharma Group Limited's TolsuraTM (SUBA-Itraconazole Capsules). A brand-new itraconazole called TOLSURA has been developed to treat systemic fungal infections such as histoplasmosis, blastomycosis, and aspergillosis.
The company Pfizer Inc. (Pfizer) finds, develops, produces, and markets biopharmaceuticals. The company provides products to treat a range of ailments, including women's health, cancer, inflammatory illnesses, immune system problems, cardiovascular, metabolic, and pain disorders. Active pharmaceutical ingredients (APIs), biosimilars, sterile injectable medications, and contract manufacturing services are also offered. For an undisclosed sum, US biotechnology and pharmaceutical giant Pfizer Inc. purchased Amplyx Pharmaceuticals Inc. in April 2021. Through this acquisition, Pfizer hopes to bolster its strategy to deepen its understanding of infectious diseases and bolster its anti-infective portfolio.
Key Companies in the aspergillosis treatment market include
Aspergillosis Treatment Industry Developments
February 2023: With its patented iSPERSE technology, PULMATRiX Inc., a clinical-stage biopharma company, is creating novel inhaled medications to treat severe illnesses. The company recently revealed the first patient dose of a Phase 2b trial that evaluated the safety and effectiveness of PUR1900 in individuals with asthma and allergic bronchopulmonary aspergillosis (ABPA). PUR1900 is a dry powder itraconazole with iSPERSE capability that is intended for pulmonary inhalation delivery.
June 2022: The introduction of the first generic version of Noxafil (posaconazole) Injection by Endo represents a noteworthy advancement in the market for aspergillosis treatments. This generic type of posaconazole injection is designed to treat invasive aspergillosis in patients 13 years of age and older, including adults and children.
| Report Attribute/Metric | Details |
| Market Size 2023 | USD 3.2 Billion |
| Market Size 2024 | USD 3.3 Billion |
| Market Size 2032 | USD 4.7 Billion |
| Compound Annual Growth Rate (CAGR) | 5.10% (2024-2032) |
| Base Year | 2023 |
| Market Forecast Period | 2024-2032 |
| Historical Data | 2019-2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Type, Drug Class, Route of Administration, Distribution Channel and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered | The US, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea |
| Key Companies Profiled | Pfizer, Inc., Astellas Pharma Inc., F2G, Merck & Co., PULMATRiX, Inc., Novartis AG, Mayne Pharma Group Limited, and Bayer AG. |
| Key Market Opportunities | · Novel Approaches to Treating Aspergillosis Improve Patient Care |
| Key Market Dynamics | · Growing Cases of Fungal Infections · Growing Number of Immunocompromised Individuals |
Frequently Asked Questions (FAQ) :
The Aspergillosis Treatment Market size was valued at USD 3.2 Billion in 2023.
The global market is projected to grow at a CAGR of 5.10% during the forecast period, 2024-2032.
North America had the largest share in the global market.
The key players in the market are Pfizer, Inc., Astellas Pharma Inc., F2G, Merck & Co., PULMATRiX, Inc., Novartis AG, Mayne Pharma Group Limited, and Bayer AG, among others.
The allergic category dominated the market in 2023.
The hospital pharmacy category had the largest share in the global market.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
